Short answer
Gossamer Bio, Inc. (GOSS) filed an 8-K current report with the SEC on July 27, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item 1.02 (Termination of a Material Definitive Agreement). Gossamer regains worldwide seralutinib rights and control across PAH, PH-ILD, and potential future indications.
Gossamer Bio, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Gossamer regains worldwide seralutinib rights and control across PAH, PH-ILD, and potential future indications
- Chiesi to pay Gossamer $5 million within 10 days for outstanding development costs
- Gossamer assumes success-based milestone payments and capped royalties on net sales of previously licensed products
- Chiesi transfers related regulatory filings and intellectual property, with licenses revocable after uncured payment breaches
- Agreement terminates the 2024 collaboration, preserves indemnities, and releases most legacy claims
Item 1.02 · Termination of a Material Definitive Agreement
- License Agreement termination, as described in Item 1.01
- Termination may alter Gossamer Bio’s rights, obligations and future economics under the agreement
Item 2.02 · Results of Operations and Financial Condition
- Preliminary cash, cash equivalents and marketable securities of approximately $57.0 million as of June 30, 2026
- Liquidity disclosure provides an early view of funding available for operations and clinical development
- Unaudited figure remains subject to quarter-end closing adjustments
Item 7.01 · Regulation FD Disclosure
- Gossamer Bio announced rights reacquisition and related license termination, signaling a material shift in its partnering strategy
- Press release includes FDA regulatory and business updates relevant to development timelines and commercialization prospects
- Full details are in Exhibit 99.1, covering the July 27, 2026 announcement
Item 8.01 · Other Events
- Seralutinib NDA submission planned for September 2026 following FDA Type B meeting
- FDA classified PROSERA statistical significance and treatment-effect magnitude as review issues, not filing issues
- NDA strategy relies on Phase 3 PROSERA, Phase 2 TORREY, and supportive analyses
- Potential FDA approval decision in Q3 2027 if the NDA is accepted for filing
- FDA approvability remains uncertain pending review of the complete NDA
Item EX-99.1 · Exhibit EX-99.1
- FDA feedback supports planned September 2026 NDA submission for seralutinib in PAH, with potential approval decision in Q3 2027 if accepted
- FDA views PROSERA efficacy and statistical significance as review issues, not filing barriers, but approval remains uncertain
- Worldwide seralutinib rights returned from Chiesi for a $5 million payment to Gossamer, with capped royalties and milestone payments owed
- Convertible note exchange reduced debt by approximately $115.9 million, leaving approximately $18.9 million of 2027 Notes outstanding
- Cash, cash equivalents and marketable securities totaled approximately $57 million at June 30, 2026; reverse split expected in or promptly after Q3 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Gossamer Bio, Inc. 8-K filings
Get the next GOSS 8-K as it lands
Follow GOSS for push alerts, or ask the research agent what this filing means.